Lori Nembirkow
General Counsel at CENTRIC BRANDS INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jason Rabin | M | 54 | 6 years | |
| Anurup S. Pruthi | M | 56 | 6 years | |
| Marc Schneider | M | 64 | 4 years | |
| Roger Czuchra | M | 54 | 5 years | |
| Jake Brandman | M | - | 8 years | |
| Sid Keswani | M | - | 3 years | |
| Tom Nevell | M | - | 8 years | |
| Joe Favuzza | M | - | 6 years | |
| Karen Coe | F | - | 6 years | |
| Joseph J. Sciametta | M | - | 4 years | |
| Ruth Hartman | F | - | 3 years | |
| Tami Fersko | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Andrew Tarshis | M | 58 | 4 years | |
| Hamish S. Sandhu | M | 61 | 10 years | |
| Timothy J. Creech | M | 63 |
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 years |
| Marc Crossman | M | 53 | 16 years | |
| Samuel J. Furrow | M | 82 | 18 years | |
| Matthew Eby | M | 52 | 4 years | |
| Randall Kessler | M | 43 | 2 years | |
| Thomas F. O'Riordan | M | 68 | 7 years | |
| Robert Taylor Petrini | M | 49 | 2 years | |
| M. Ross Johnson | M | 79 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 4 years |
| Joseph M. Dahan | M | 56 | 8 years | |
| Michael F. Buckley | M | 60 | 2 years | |
| Robert Ross | M | 55 | 1 years | |
| William Sweedler | M | 57 | 4 years | |
| Joanne Calabrese | F | 65 | 4 years | |
| Kelly Hoffman | M | 66 | 14 years | |
| Suhail Rizvi | M | 58 | 13 years | |
| Glenn Krevlin | M | 64 | 2 years | |
| Kent A. Savage | M | 62 | 17 years | |
| Walter McLallen | M | 58 | 4 years | |
| Sarah Choufani | F | - | - | |
| Myung-Cheol Kang | M | - |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 8 years |
| Diego Miralles | M | 62 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 5 years |
| Samuel Hopkins | M | - |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 6 years |
| Peter Kim | M | 53 | 2 years | |
| Pamela Gill Alabaster | F | - | - | |
| Sherman Edmiston | M | 61 | - | |
| Samuel Joseph Furrow | M | 50 | - | |
| Michael Alrutz | M | 54 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 9 years |
| Walter Capone | M | 59 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 5 years |
| Patrick Bartels | M | 49 | - | |
| Marc Saffer | M | 66 | 1 years | |
| Marjorie Bowen | F | 58 | - | |
| Kevin Tang | M | 57 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 years |
| E. Gary Cook | M | 79 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 years |
| Steven Skolsky | M | 68 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 2 years |
| Richard Allan Quiroga | M | 64 | 2 years | |
| Julian Baker | M | 57 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 years |
| Felix Baker | M | 55 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 years |
| Laura Ritchey | F | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 52 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Lori Nembirkow
- Personal Network
